🔷 Stock of the Week – Strides Pharma Science Ltd. (STAR)

📉 GoalFi Portfolio Snapshot – June 15, 2025

Author

GoalFi Social
June 15, 2025

Guided by a vision to make financial planning accessible and impactful.

Hello ,

Markets move fast; but behind every sharp move lies a story worth understanding. Our Stock of the Week captures companies showing meaningful momentum, backed by fundamentals and strategic relevance. These weekly spotlights aim to offer quick, insightful takeaways for curious investors.

Today’s spotlight is on:

🔷 Stock of the Week – Strides Pharma Science Ltd. (STAR)

🧬 Innovating Growth – Quality Mix | 📆 Coverage date: 10-Dec-2024
💼 Sector: Pharmaceuticals | 🧪 Market Cap: Mid-Cap

🏢 Company Profile

Strides Pharma Science Ltd. is a global pharmaceutical player focused on R&D-led generics and specialty pharma. It operates across regulated markets like the US, UK, Australia, and EMs. The company’s differentiated offerings and global footprint place it at the forefront of India’s export-led pharma growth.

📈 Weekly Performance Snapshot

Metric

Value

Price

₹882.45

Weekly Change

🔼 +12.8%

Smallcase Entry Price

₹748.25

Return Since Entry

🟢 +17.94%

🧾 What’s Driving STAR’s Momentum?

🔹 Q4 FY25 (Mar '25) vs Q3 FY25 (Dec '24)

  • Revenue: ₹1,190 Cr ▲ from ₹1,154 Cr

  • Operating Profit: ₹218 Cr ▲ from ₹210 Cr

  • Operating Margin: Stable at 18%

  • Net Profit: ₹86 Cr ⬇ from ₹90 Cr

  • EPS: ₹8.91 ⬇ from ₹9.54

🟢 Consistent revenue and margins signal business stability.
🟠 Minor dip in PAT due to lower other income.

🔹 Y-o-Y Turnaround: FY24 → FY25

  • Sales Growth: ₹4,051 Cr → ₹4,565 Cr (+12.7%)

  • Operating Profit: ₹568 Cr → ₹803 Cr (+41.3%)

  • Net Profit: ₹-94 Cr → ₹3,598 Cr

  • EPS: ₹-7.68 → ₹389.75

🟢 Strides has delivered a sharp recovery from last year’s losses, driven by operating leverage, improved product mix, and better export realization.

🔍 Analyst View

📌 Key Positives:

  • ✅ Double-digit margin stability for 4 straight quarters

  • ✅ Strong U.S. and Africa market traction

  • ✅ Interest expense reduction (₹70 Cr → ₹50 Cr)

  • ✅ Model-confirmed breakout on price & earnings

📌 Things to Watch:

  • ⚠️ Volatility in Other Income

  • ⚠️ Currency impact on export-heavy revenue

Tune in for practical investment advice that anyone can apply, whether you're a beginner or looking to enhance your existing portfolio.

🧭 GoalFi’s Take

Strides Pharma is emerging from a tough FY24 with renewed operating strength. Its steady margin delivery and scale-up in formulations exports make it a top contender in our “Quality + Growth” segment.

🔷 Why it fits our model:

  • 📈 Earnings Momentum

  • 💡 Operating Leverage Kicker

  • 🔍 Valuation Catch-up Story

📬 Ready to Ride India’s Next Growth Wave?

🔹 Already invested in the model? ✅ You’re all set
🔹 Not yet invested? 🚀 Subscribe to “Innovating Growth – Quality Mix” Now – here is the link:👉https://tinyurl.com/3xab2mh5

📩 Have questions? Email us at [email protected]
💬 Or start a chat at chat.goalfi.app

📣 Stay Ahead with GoalFi

Make sure to explore our curated portfolios that align with your financial goals.

Explore GoalFi Smallcases Now: https://goalfiresearch.smallcase.com

We hope this update helps you stay informed and empowered in your investment journey. Feel free to reach out if you have any questions or need personalized advice.

Best Regards,
Team GoalFi

Disclaimer: This newsletter is intended solely for educational and informational use. It does not constitute financial advice or serve as a promotional message.